CD274 and diffuse large B-cell lymphoma: Overall, these findings indicated that anti-PD-1/PD-L1 therapy could be a novel therapeutic approach for A-DLBCL.mPD-L1+ DLBCL is defined as 20% or more PD-L1+ nonmalignant cells among the total tissue cellularity in PD-L1– DLBCL.